ClinicalTrials.gg
RecruitingNCT03965299TASCIUpdated Nov 5, 2026

Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury

An interventional study of VERUM TTNS and SHAM TTNS in Spinal Cord Injury, Acute, sponsored by University of Zurich. Recruiting at 4 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Zurich · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 5 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Spinal Cord Injuries by University of Zurich — 7 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · University of Zurich.

Planned enrollment
3rd of 14
114 · median 64
Started
2019
with 1 other
No phase
12 of 24
3 open now
Registered
18th of 24
by date

Among the 24 studies in Spinal Cord Injuries by University of Zurich, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 with no phase, and was the 18th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

7 of the 24 studies in Spinal Cord Injuries by University of Zurich are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Spinal Cord Injuries by University of Zurich, or all of them as a file.
02

Study summary

Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.

This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.

Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.

03

Conditions studied

  • Spinal Cord Injury, Acute

Keywords

  • randomized, sham-controlled, double-blind trial
  • transcutaneous tibial nerve stimulation
  • spinal cord injury
  • neurogenic detrusor overactivity
  • neuromodulation
  • electrical stimulation
  • paraplegia; tetraplegia
  • urodynamics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Patients with acute SCI (traumatic SCI and sudden onset (\<7 days) non-traumatic SCI) within 40 days after injury
  • Patients with acute SCI at cervical or thoracic level
  • Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI)

    • no percutaneous tibial nerve stimulation (PTNS)
    • no functional electrical stimulation (FES), apart from upper limb FES
    • no electrical muscle stimulation (EMS)

Exclusion criteria

Exclusion Criteria:

  • to the product
  • DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit
  • Treatment with antimuscarinics or with mirabegron
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Neuromodulation treatment for urological or bowel indication in the last six months or ongoing
  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
  • Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude \< 1mV)
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological )
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    VERUM transcutaneous tibial nerve stimulation (TTNS)

    Device: VERUM TTNS

  • Sham comparator
    SHAM transcutaneous tibial nerve stimulation (TTNS)

    Device: SHAM TTNS

Interventions

  • DeviceVERUM TTNS

    * Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments * During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

  • DeviceSHAM TTNS

    * Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments * During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

06

What researchers measure

Primary outcomes

  1. The occurrence of neurogenic DO jeopardizing the upper urinary tract

    Defined as composite measure: Urodynamic assessment establishing DO amplitude ≥40 cmH2O; or else initiation of DO treatment (with antimuscarinics and/or intradetrusor onabotulinumtoxinA injections)

    Time frame: up to 12 months after SCI

Secondary outcomes

  1. Volumetric changes during urodynamics and their relation to clinical outcomes

    Cystometric capacity \[mL\], volume at first DO \[mL\], voided volume \[mL\] and post void residual \[mL\] as assessed by urodynamic measurement

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  2. Changes in bladder compliance [mL/cmH2O] during urodynamics and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  3. Pressure changes during urodynamics and their relation to clinical outcomes

    Maximum DO amplitude \[cmH2O\], detrusor leak-point pressure \[cmH2O\], maximum detrusor pressure \[cmH2O\] during storage phase, maximum detrusor pressure \[cmH2O\] during voiding phase, detrusor pressure at maximum flow rate \[cmH2O\] as assessed by urodynamic measurement

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  4. Changes in maximum flow rate [mL/s] as assessed by urodynamics and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  5. Changes in vesicoureterorenal reflux (VUR) as assessed by videography during urodynamics and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  6. Changes in pelvic floor activity as assessed by electromyography (EMG) during urodynamics and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  7. Changes in bladder storage and voiding parameters and their relation to clinical outcomes

    Assessed by a bladder diary

    Time frame: Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  8. Changes in bowel diary parameters and their relation to clinical outcomes

    Assessed by a bowel diary

    Time frame: Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  9. Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes

    The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."

    Time frame: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  10. Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes

    The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).

    Time frame: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  11. Changes in Qualiveen questionnaire scores and their relation to clinical outcomes

    Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).

    Time frame: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  12. Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes

    The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  13. Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes

    The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  14. Changes in International Spinal Cord Society (ISCoS) Female / Male sexual function data sets and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  15. Changes in Neurogenic Bowel Dysfunction (NBD) score and their relation to clinical outcomes

    The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).The NBD score is assessed by using the international spinal cord injury (ISCoS) bowel function basic data set.

    Time frame: Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  16. Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes

    Initial sensation \[mL\], volume at urge to defecate \[mL\], maximum tolerated volume \[mL\] as assessed by rectal sensitivity testing; rectal capacity \[mL\] assessed by barostat assessment

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  17. Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes

    Basal internal anal sphincter pressure \[mmHg\], squeeze external anal sphincter pressure \[mmHg\], relaxation internal anal sphincter pressure during defecation \[%, mmHg\], intraabdominal pressure during defecation \[mmHg\]

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  18. Changes in rectal compliance [mL/cmH2O] during anorectal manometry and barostat assessment and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  19. Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes

    Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types of manometric patterns (I-IV) that are identified through manometric assessments

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  20. Changes International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment to quantify the severity of the spinal cord injury

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  21. Changes in Lower Extremities Motor Scale (LEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  22. Changes in Upper Extremities Motor Scale (UEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  23. Changes in Spinal Cord Independence Measure III (SCIM-III) and their relation to clinical outcomes

    The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  24. Changes in spasticity in the knee and elbow flexors and extensors from the Modified Ashworth Scale (MAS) assessment and their relation to clinical outcomes

    The MAS is a 5-point nominal scale that uses subjective clinical assessments of muscle tone ranging from 0 - 'No increases in tone' to 4 - 'Limb rigid in flexion or extension'. A grade of (1+) indicates resistance in the movement.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  25. Changes in spasticity in daily life as assessed by the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) questionnaire and their relation to clinical outcomes

    The SCI-SET ("Spinal Cord Injury Spasticity Evaluation Tool ") score is based on questions concerning the positive and negative effects of spasticity on different areas of daily life. Each of the 35 items are rated on a 7-point scale (-3=extremely problematic; 0=no effect; 3=extremely helpful). Calculations include counts and sum scores of areas of daily life where spasticity is problematic (count range: 0 to 35, sum score range: 35 to 0) or helpful (counts range: 0 to 35, sum score range: 0 to +35) as well as a mean score of all applicable items (range: -3 to +3)

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  26. Changes in neurophysiology measurements of evoked potentials (EPs) as well as nerve conduction measurements and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  27. Changes in lower urinary tract (LUT) neurophysiology: Current perception thresholds (CPTs) and LUT sensory evoked potentials (LUTSEPs) with their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  28. Changes in frequency power of surface electromyography (EMG) and electroencephalography (EEG) and their relation to clinical outcomes

    Fast Fourier Transformation analysis for delta, theta, alpha, beta, and gamma band power as assessed via EEG of the cortex and EMG of the muscle

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  29. Changes in EMG and EEG coherence measures and their relation to clinical outcomes

    Coherence for EEG and EMG signals computed as cortico-muscular, inter- and intra-muscular coherence for typical EEG/EMG frequency bands (delta, theta, alpha, beta, and gamma).

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  30. Changes in white and gray matter area in the lumbosacral enlargement (LSE) and their relation to clinical outcomes

    White and gray matter areas are obtained by segmenting the T2\*-weighted MRI images for white and gray matter at the level of LSE

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  31. Changes in white and gray matter area in upper cervical cord (at C2/C3) and their relation to clinical outcomes

    Obtained by segmenting the T2\*-weighted MRI images for white and gray matter at the vertebral level C2/C3.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  32. Changes in white and gray matter volume of the conus medullaris (CM) and their relation to clinical outcomes

    White and gray matter volume are obtained by segmenting the T2\*-weighted MRI images for white and gray matter in the CM

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  33. Changes in gray and white matter volume in the brain and their relation to clinical outcomes

    Gray and white matter volume in the brain are computed by feeding the whole-brain T1-weighted MRI images into a voxel-based morphometry algorithm. Changes in the gray and white matter volume will be evaluated in urologically relevant brain areas.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  34. Changes in fractional anisotropy (FA) in the brain and spinal cord and their relation to clinical outcomes

    FA is a common dimensionless measure used in Diffusion Tensor Imaging (DTI) studies and ranges from 0, isotropic movement of water molecules (e.g., cerebrospinal fluid), to 1, fully anisotropic movement of water molecules (e.g., fiber bundles).

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  35. Changes in diffusivity in the brain and spinal cord and their relation to clinical outcomes

    Mean, axial, and radial diffusivity (MD, AD, RD) are common measures used in DTI studies providing information about the integrity of the underlying tissue.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  36. Changes in brain and spinal cord tissue microstructure and their relation to clinical outcomes

    Quantitative tissue parameters assessed using MRI Multi-Parameter Mapping.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  37. Expression profile of microRNA (miRNA) in urine and blood as well as their relation to clinical outcomes

    MicroRNA (miRNA) sequencing is used to identify regulated miRNAs specific to TTNS intervention in urine and blood.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  38. Changes in inflammatory markers in bladder tissue, blood, and urine, as well as their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  39. Changes in levels of neurotransmitters (neurotrophins) in blood, and urine, as well as their relation to clinical outcomes

    Analysis will be performed using ELISA to detect molecules likely to be involved in the underlying molecular mechanisms of neuromodulation.

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  40. Changes in the composition of urinary and stool microbiome and their relation to clinical outcomes

    Gut and bladder microbial patterns are determined from stool and urine samples

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

  41. Changes in bladder tissue and their relation to clinical outcomes

    Time frame: Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Other outcomes

  1. Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of adverse events (AEs) and serious adverse events (SAEs) for the following categories:

    * infection - Urinary Tract Infection (UTI) * infection - other than UTI * skin irritation at the electrode site * irritation-related symptoms (e.g. dysuria, hematuria) immediately following a LUT intervention * neuro-urological deterioration * pressure ulcer * neurological deterioration * increase in pain * increase in spasticity * deep vein thrombosis / pulmonary embolism * autonomic dysreflexia * transfer/admittance to an acute care facility

    Time frame: During complete study period, up to 12 months

07

Study locations

4 of 4 sites recruiting
  • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital
    Zurich, Canton of Zurich 8008, Switzerland
    Recruiting
    • Thomas M Kessler, Prof. Dr. med. · Contactthomas.kessler@balgrist.ch · +41 44 386 39 07
    • Thomas M Kessler, Prof. Dr. med. · Principal investigator
  • REHAB Basel
    Basel, Switzerland
    Recruiting
    • Sandra Möhr, pract. med. · Contacts.moehr@rehab.ch
    • Sandra Möhr, pract. med. · Principal investigator
  • Swiss Paraplegic Centre
    Nottwil, Switzerland
    Recruiting
  • Spinal Cord Injury Department, Clinique romande de réadaption
    Sion, Switzerland
    Recruiting
08

References and documents

Publications

  • Birkhauser V, Liechti MD, Anderson CE, Bachmann LM, Baumann S, Baumberger M, Birder LA, Botter SM, Bueler S, Cruz CD, David G, Freund P, Friedl S, Gross O, Hund-Georgiadis M, Husmann K, Jordan X, Koschorke M, Leitner L, Luca E, Mehnert U, Mohr S, Mohammadzada F, Monastyrskaya K, Pfender N, Pohl D, Sadri H, Sartori AM, Schubert M, Sprengel K, Stalder SA, Stoyanov J, Stress C, Tatu A, Tawadros C, van der Lely S, Wollner J, Zubler V, Curt A, Pannek J, Brinkhof MWG, Kessler TM. TASCI-transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial. BMJ Open. 2020 Aug 13;10(8):e039164. doi: 10.1136/bmjopen-2020-039164. PubMed 32792454 ↗
  • Liechti MD, van der Lely S, Stalder SA, Anderson CE, Birkhauser V, Bachmann LM, Brinkhof MWG, Curt A, Jordan X, Leitner L, Mehnert U, Mohr S, Pannek J, Schubert M, Kessler TM; TASCI Study Group. Update from TASCI, a Nationwide, Randomized, Sham-controlled, Double-blind Clinical Trial on Transcutaneous Tibial Nerve Stimulation in Patients with Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity. Eur Urol Focus. 2020 Sep 15;6(5):877-879. doi: 10.1016/j.euf.2019.09.019. Epub 2019 Oct 8. PubMed 31601539 ↗
  • Anderson CE, Birkhauser V, Stalder SA, Bachmann LM, Curt A, Jordan X, Leitner L, Liechti MD, Mehnert U, Mohr S, Pannek J, Schubert M, van der Lely S, Kessler TM, Brinkhof MWG. Optimizing clinical trial design using prospective cohort study data: a case study in neuro-urology. Spinal Cord. 2021 Sep;59(9):1003-1012. doi: 10.1038/s41393-020-00588-z. Epub 2020 Nov 24. PubMed 33235299 ↗
  • Bueler S, Yiannakas MC, Damjanovski Z, Freund P, Liechti MD, David G. Optimized multi-echo gradient-echo magnetic resonance imaging for gray and white matter segmentation in the lumbosacral cord at 3 T. Sci Rep. 2022 Oct 3;12(1):16498. doi: 10.1038/s41598-022-20395-1. PubMed 36192560 ↗
  • Bueler S, Freund P, Kessler TM, Liechti MD, David G. Improved inter-subject alignment of the lumbosacral cord for group-level in vivo gray and white matter assessments: A scan-rescan MRI study at 3T. PLoS One. 2024 Apr 16;19(4):e0301449. doi: 10.1371/journal.pone.0301449. eCollection 2024. PubMed 38626171 ↗
  • Stalder SA, van der Lely S, Anderson CE, Birkhauser V, Curt A, Gross O, Leitner L, Mehnert U, Schubert M, Tornic J, Kessler TM, Liechti MD. Development of a Sham Protocol to Investigate Transcutaneous Tibial Nerve Stimulation in Randomised, Sham-Controlled, Double-Blind Clinical Trials. Biomedicines. 2023 Jul 7;11(7):1931. doi: 10.3390/biomedicines11071931. PubMed 37509569 ↗
  • Beghini L, Bueler S, Liechti MD, Jaffray A, David G, Vannesjo SJ. Optimized navigator-based correction of breathing-induced B0 field fluctuations in multi-echo gradient-echo imaging of the spinal cord. Magn Reson Med. 2025 Jul;94(1):215-230. doi: 10.1002/mrm.30475. Epub 2025 Mar 4. PubMed 40034000 ↗
  • Bueler S, Anderson CE, Birkhauser V, Freund P, Gross O, Kessler TM, Kundig CW, Leitner L, Mahnoor N, Mehnert U, Rothlisberger R, Stalder SA, van der Lely S, Zipser CM, David G, Liechti MD. Remote neurodegeneration in the lumbosacral cord one month after spinal cord injury: a cross-sectional MRI study. Ann Clin Transl Neurol. 2025 Mar;12(3):523-537. doi: 10.1002/acn3.52298. Epub 2025 Jan 27. PubMed 39869509 ↗

Individual participant data

Plan to share: Yes — All individual participant data (IPD) and data dictionaries that underlie results in a publication are to be uploaded to a public data registry in cases where this can be done without compromising patient privacy. Given the small size of the dataset and that spinal cord injury (SCI) is a rare condition, to ensure identity protection any publicly available dataset(s) will be modified to reduce the number of indirect identifier variables, e.g. continuous variables such as age will be grouped, categorical or binary variables with small group numbers such as study centre will not be provided. When data sets cannot be sufficiently de-identified to be made publicly available, they will be made available upon reasonable request. Data judged to be confidential to participants or the participating study centers will not be released, but efforts will be made to provide scientifically meaningful equivalent information.

Supporting information: Analytic code

Time frame: Post-publication data packages, containing the analysis data set presented in scientific reports will be available starting 6 months after the publication date. Data that are not being prepared for publication will be available to secondary users starting 4 years after study completion or discontinuation. All data will be kept for at least 10 years after study completion or discontinuation.

Access criteria: Requests for data access will be reviewed by the TASCI steering committee, which includes the four project PIs and representatives from each of the participating study centers. The steering committee will request a project plan, including at a minimum an abstract and a list of author names and roles, from the leaders of all projects wishing to use TASCI study data. Project plans will be evaluated on the basis of scientific validity, and also on whether they include adequate measures to protect patient privacy. Secondary users will be asked to sign a data use agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Sep 2028, 111 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 111 months is above that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Sep 2026 → Sep 2028 and completion Sep 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2019
First posted
May 29, 2019
StartActual
Jun 19, 2019
Primary completionEst.
Sep 30, 2028was Sep 2026
CompletionEst.
Sep 30, 2028was Sep 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 30, 2028
Nov 5, 2026
Study completion
Sep 30, 2026→Sep 30, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Sep 30, 2026→Sep 30, 2028
    Study completion Sep 30, 2026→Sep 30, 2028
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03965299
Collaborators
Swiss National Science Foundation, Clinique Romande de Readaptation, Rehab Basel, Swiss Paraplegic Research, Nottwil, BioMedical Research Forschungslabor für Urologie, University of Bern, Universidade do Porto, Center for Lower Urinary Tract Research School of Medicine, University of Pittsburgh
Responsible party
Sponsor
First posted
May 29, 2019
Start date
Jun 19, 2019
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Thomas M. Kessler, Prof. Dr. med.
Contact
thomas.kessler@balgrist.ch
+41 44 386 39 07
Martina D. Liechti, Dr. sc. ETH
Contact
martina.liechti@balgrist.ch
+41 44 386 39 07
Thomas M. Kessler, Prof. Dr. med.
study chair · University of Zurich
Thomas M. Kessler, Prof. Dr. med.
principal investigator · Balgrist University Hospital
Armin Curt, Prof. Dr. med.
principal investigator · Balgrist University Hospital
Martin Brinkhof, Dr.
principal investigator · Swiss Paraplegic Research, Nottwil
Jürgen Pannek, Prof. Dr. med.
principal investigator · Swiss Paraplegic Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion